FIG. 5.
Pharmacokinetic analysis of unmodified VSV-G-HIV and PEGylated VSV-G-HIV in C57BL/6 mice. Equal titers (2.1 × 107 TU) of native or PEGylated VSV-G-HIV expressing E. coli beta-galactosidase were administered by tail vein injection to C57BL/6 mice. The viral titers (in TU per milliliter) of unmodified VSV-G-HIV (A) and PEGylated virus (C) were determined by serial dilution of whole blood and infection of 293T cells. The p24 levels of unmodified virus (B) and PEGylated VSV-G-HIV (D) were determined from serum by ELISA. (E) Twelve-hour kinetic profile of circulating infectious virus in C57BL/6 mice after intravenous injection of either PEGylated VSV-G pseudotyped HIV (PEG VSVG) or unmodified vector (VSVG). (F) Extended kinetic profile of circulating HIV p24 protein in C57BL/6 mice. Each data point reflects the average concentration obtained from three animals within each treatment group. The error bars represent the standard deviations of the data.